Sosei Heptares Eyes Asia Build-Out On Internal, External Assets
Parallel To Partnering
Japan-UK firm is looking to build on a combination of internal and external assets to pursue a more independent business development path in Japan and beyond, in parallel with ongoing discovery and development collaborations.
You may also be interested in...
Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
Sosei Bolsters GPCR Focus With AbbVie Neurology Deal
The Japanese firm has expanded its partnership with AbbVie into the neurology space, where it hopes to use its unique platform technology to develop up to three drug candidates targeting ‘challenging’ G protein-coupled receptor targets.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Leqembi bodes well for Biogen; AbbVie predicts US Humira erosion; Sanofi’s R&D chief moves on; Roche’s ophthalmology plans; and Scrip Asks what 2023 holds for AI in pharma.